Rockwell Medical RMTI shares are trading higher Tuesday after the company announced U.S. availability of Triferic AVNU for replacement of iron and maintenance of hemoglobin in patients on hemodialysis.
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic and Calcitriol.
Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease.
Rockwell Medical stock was up 30.41% at $1.93. The stock has a 52-week high of $3.85 and a 52-week low of 83 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
